Key result
Cyclosporine and LVAD support enable successful explantation and ~40-point LVEF recovery in giant cell myocarditis.
Why the study?
Although immunotherapy combined with mechanical circulatory support seems to improve outcomes in fulminant giant cell myocarditis, characterizing definitive clinical outcomes remains challenging and the autoimmunity associated with its onset remains controversial.
Can cyclosporine-based immunosuppression combined with mechanical circulatory support and extended thymectomy achieve bridge to recovery in a patient with fulminant giant cell myocarditis and myasthenia gravis?
Case Report (n=1)
No
Can cyclosporine-based immunosuppression combined with mechanical circulatory support and extended thymectomy achieve bridge to recovery in a patient with fulminant giant cell myocarditis and myasthenia gravis?
This case demonstrates that cyclosporine-based immunosuppression combined with mechanical circulatory support and extended thymectomy can achieve complete cardiac recovery and LVAD explantation in fulminant giant cell myocarditis associated with myasthenia gravis, even in the absence of thymoma or known anti-striational antibodies.
Answers are grounded in this paper and cite their sources.
May support cyclosporine-based immunosuppression with LVAD in fulminant giant cell myocarditis with myasthenia gravis; leaves open need for prospective validation.
BACKGROUND: A recently indicated immunotherapy strategy, combined with mechanical circulatory support (MCS), seems to improve outcomes in patients with fulminant giant cell myocarditis (GCM). However, characterizing a definitive clinical outcome of this strategy remains challenging, and the autoimmunity associated with the onset of GCM remains controversial. CASE SUMMARY: A 26-year-old man with poor control of atopic dermatitis and ulcerative colitis presented with cardiogenic shock requiring MCS. He was diagnosed with fulminant GCM; hence, immunotherapy (including steroids and intravenous immunoglobulin) was administered and an extracorporeal left ventricular assist device (LVAD) was needed. As the patient complained of prominent fatigue and double vision before myocarditis onset, and acetylcholine receptor-binding antibody titres were elevated, he was diagnosed with myasthenia gravis (MG). No anti-striational antibodies known to be associated with GCM in patients with MG were found in the patient's serum. Cyclosporin-based immunosuppression under LVAD therapy led to an almost complete resolution of his muscle weakness, intermittent ptosis, and cardiac dysfunction along with the histopathological remission of GCM resulting in LVAD removal. He remained at home without recurrence of GCM and worsening symptoms of MG over the 6-month period following discharge. DISCUSSION: We describe a case of GCM with multiple autoimmune disorders, which recovered by treatment with early cyclosporin-based immunosuppressive therapy under LVAD therapy. The present case suggests the involvement of unknown anti-striational antibodies in the development of GCM in patients with MG and may provide information to guide a novel therapeutic regimen for patients with fulminant GCM requiring mechanical circulatory support.
No takes yet. Share an insight, caveat, or question.
Yagi et al. (2022) conducted a case report in Fulminant giant cell myocarditis with cardiogenic shock and myasthenia gravis (n=1). Cyclosporine-based immunosuppression combined with steroids, intravenous immunoglobulin, mechanical circulatory support (BiVAD/LVAD), and extended thymectomy was evaluated on Bridge to recovery (LVAD explantation, LVEF improvement, and histopathological remission of giant cell myocarditis). Cyclosporine-based immunosuppression under LVAD support enabled LVAD removal on Day 41 and improved LVEF from 16% to 56% with no recurrence over 6 months in a fulminant giant cell myocarditis patient.
Synapse has enriched 10 related papers. Consider them for comparative context: